Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: A randomized controlled trial

Microbiology and Immunology

Volumn 55, Issue 11, 2011, Pages 783-789

  Uno, Shingo ^a   Kimachi, Kazuhiko ^b   Kei, Junko ^a   Miyazaki, Keiichiro ^a   Oohama, Ayano ^a   Nishimura, Tomohiro ^b   Ibaragi, Kayo ^b   Odoh, Koichi ^a   Kudo, Yasuhiro ^a   Kino, Yoichiro ^b  

^a Chemo Sero Therapeutic Research Institute   (Japan)

^b Kikuchi Research Center   (Japan)

Author keywords

HI antibody response; Pandemic H1N1 2009 vaccine; Seasonal influenza vaccine

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG SAFETY; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT OUTCOME; URTICARIA; VACCINATION; VOMITING;

ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; HUMAN EXPERIMENTATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; JAPAN; MALE; MIDDLE AGED; VACCINATION;

EID: 80755161302     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2011.00381.x     Document Type: Article

References (18)

1. Centers for Disease Control and Prevention (CDC). (2009) Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. Morb Mortal Wkly Rep 58: 400-2.
2. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360: 2605-15.
3. World Health Organization. (2009) New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wikly Epidemiol Rec 84: 249-57.
4. Parkman P.D., Hopps H.E., Rastogi S.C., Meyer H.M. Jr. (1977) Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 136: S722-30.
5. Girard M.P., Katz J., Pervikov Y., Palkonyay L., Kieny M. (2010) Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine 28: 6811-20.
6. Ministry of Health, Labour and Welfare. Ethical guidelines for clinical studies. 30 July 2003. (Amended 28 December 2004). Available from.
7. World Health Organization. Summary of status of development and availability of A/California/7/2009 (H1N1)-like candidate vaccine viruses and potency testing reagents. 24 May 2010. Available from.
8. World Health Organization, Department of Communicable Disease Surveillance and Response. WHO manual on animal influenza diagnosis and surveillance. May 2002. Available from.
9. Grant S., Aitchison T., Henderson E., Christie J., Zare S., McMurray J., Dargie H. (1999) A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest 116: 1208-17.
10. European Medicines Evaluation Agency. 18 December 2008. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorization application. Available from.
11. European Medicines Evaluation Agency. 24 January 2007. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. Available from.
12. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. May 2007. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Available from.
13. Kim J.H., Skountzou I., Compans R., Jacob J. (2009) Original antigenic sin responses to influenza viruses. J Immunol 183: 3294-301.
14. Lambert J.F., Nydegger U.E. (2010) Geo-epidemiology of autoimmune hemolytic anemia. Autoimmun Rev 9: A350-4.
15. Wu J., Zhong X., Li C.K., Zhou J.F., Lu M., Huang K.Y., Dong M., Liu Y., Luo F.J., Du N., Chui C., Liu L.Q., Smith N.M.G., Li B., Shi N.M., Song L.F., Gao Y., Wang D.Y., Wang X., Zhu W.F., Yan Y., Li Z., Chen J.T., McMichael A.J., Yin W.D., Xu X.N., Shu Y. (2011) Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. Vaccine 29: 1009-16.
16. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., Nissen M., Marshall H., Booy R., Heron L., Hartel G., Lai M., Basser R., Gittleson C., Greenberg M. (2010) Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: a randomized trial. JAMA 303: 37-46.
17. Roman F., Vaman T., Kafeja F., Hanon E., Van Damme P. (2010) AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 51: 668-77.
18. Vajo Z., Tamas F., Sinka L., Jankovics I. (2010) Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 375: 49-55.